Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer’s Disease

doi:10.2174/1567205018666211022164952

摘要

背景：脑脊液 (CSF) 生物标志物与轻度认知障碍向阿尔茨海默病 (AD) 的转变有关，但它们对后期终点的预测价值的评估较少，结果不一致。目的：我们研究了 CSF 淀粉样蛋白-β1-42 (Aβ42)、磷酸化 tau (P-tau) 和总 tau (T-tau) 与养老院安置 (NHP) 时间和诊断后预期寿命之间的潜在关系。方法：这项前瞻性观察研究包括 129 名临床诊断为轻度至中度 AD 并接受腰椎穿刺的门诊患者。使用 xMAP 技术分析 CSF 生物标志物。记录住院和死亡日期。结果：经过 20 年的随访，123 名患者（95%）死亡。具有异常 P-tau 和 T-tau (A+ T+ (N)+) 的参与者比具有正常 P-tau/异常 T-tau (A+ T- (N)+) 的参与者更早死亡（平均，80.5 岁 vs. 85.4 岁）。在较低的 Aβ42 和较短的 NHP 时间（p = 0.017）以及较高的 P-tau 和较年轻的死亡年龄（p = 0.016）之间证明了线性关联。 AD 诊断后的存活率与 CSF 生物标志物之间未检测到相关性。在性别和年龄调整的 Cox 回归模型中，较高的 P-tau 和 T-tau 是诊断后寿命较短的独立预测因子。在多变量 Cox 模型中，年龄较大和基线认知状态较低，但 tau 不升高，显着促进了收容和死亡。结论：这些发现表明 CSF 生物标志物水平在 AD 的痴呆阶段趋于稳定，这可能会限制其与临床终点（如 NHP 和生存时间）的可能关系。然而，生物标志物反映了 AD 的主要病理生理学。特别是，病理性 tau 与更晚期的疾病、更年轻的发病年龄和更早的死亡有关。

关键词: 阿尔茨海默病、疗养院安置、死亡率、纵向研究、预测因子、脑脊液生物标志物、AT(N)、Tau。

« Previous Next »

[1] 
Prince M, Prina M, Guerchet M. World Alzheimer Report 2013 Journey of Caring An analysis of long-term care for dementia. London: Alzheimer’s Disease International 2013.
[2] 
Hatoum HT, Thomas SK, Lin SJ, Lane R, Bullock R. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer’s disease patients receiving rivastigmine or donepezil. J Med Econ  2009; 12(2): 98-103.
[http://dx.doi.org/10.3111/13696990903004039] [PMID: 19492974] 
[3] 
Cepoiu-Martin M, Tam-Tham H, Patten S, Maxwell CJ, Hogan DB. Predictors of long-term care placement in persons with dementia: a systematic review and meta-analysis. Int J Geriatr Psychiatry  2016; 31(11): 1151-71.
[http://dx.doi.org/10.1002/gps.4449] [PMID: 27045271] 
[4] 
Gaugler JE, Kane RL, Kane RA, Clay T, Newcomer R. Caregiving and institutionalization of cognitively impaired older people: utilizing dynamic predictors of change. Gerontologist  2003; 43(2): 219-29.
[http://dx.doi.org/10.1093/geront/43.2.219] [PMID: 12677079] 
[5] 
Wattmo C, Wallin AK, Londos E, Minthon L. Risk factors for nursing home placement in Alzheimer’s disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist  2011; 51(1): 17-27.
[http://dx.doi.org/10.1093/geront/gnq050] [PMID: 20562471] 
[6] 
Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med  2004; 140(7): 501-9.
[http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00008] [PMID: 15068977] 
[7] 
Rountree SD, Chan W, Pavlik VN, Darby EJ, Doody RS. Factors that influence survival in a probable Alzheimer disease cohort. Alzheimers Res Ther  2012; 4(3): 16.
[http://dx.doi.org/10.1186/alzrt119] [PMID: 22594761] 
[8] 
Wattmo C, Londos E, Minthon L. Longitudinal associations between survival in Alzheimer’s disease and cholinesterase inhibitor use, progression, and community-based services. Dement Geriatr Cogn Disord  2015; 40(5-6): 297-310.
[http://dx.doi.org/10.1159/000437050] [PMID: 26335053] 
[9] 
Tilvis RS, Strandberg TE, Juva K. Apolipoprotein E phenotypes, dementia and mortality in a prospective population sample. J Am Geriatr Soc  1998; 46(6): 712-5.
[http://dx.doi.org/10.1111/j.1532-5415.1998.tb03805.x] [PMID: 9625186] 
[10] 
Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry  2012; 69(1): 98-106.
[http://dx.doi.org/10.1001/archgenpsychiatry.2011.155] [PMID: 22213792] 
[11] 
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement  2018; 14(4): 535-62.
[http://dx.doi.org/10.1016/j.jalz.2018.02.018] [PMID: 29653606] 
[12] 
Wallin AK, Blennow K, Andreasen N, Minthon L. CSF biomarkers for Alzheimer’s Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord  2006; 21(3): 131-8.
[http://dx.doi.org/10.1159/000090631] [PMID: 16391474] 
[13] 
Boumenir A, Cognat E, Sabia S, et al. CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease. Alzheimers Res Ther  2019; 11(1): 29.
[http://dx.doi.org/10.1186/s13195-019-0481-4] [PMID: 30922415] 
[14] 
Degerman Gunnarsson M, Ingelsson M, Blennow K, Basun H, Lannfelt L, Kilander L. High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease. Alzheimers Res Ther  2016; 8(1): 22.
[http://dx.doi.org/10.1186/s13195-016-0191-0] [PMID: 27263933] 
[15] 
Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology  2010; 74(19): 1531-7.
[http://dx.doi.org/10.1212/WNL.0b013e3181dd4dd8] [PMID: 20458070] 
[16] 
Degerman Gunnarsson M, Lannfelt L, Ingelsson M, Basun H, Kilander L. High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer’s disease. Dement Geriatr Cogn Disord  2014; 37(3-4): 196-206.
[http://dx.doi.org/10.1159/000355556] [PMID: 24157938] 
[17] 
Nägga K, Wattmo C, Zhang Y, Wahlund LO, Palmqvist S. Cerebral inflammation is an underlying mechanism of early death in Alzheimer’s disease: a 13-year cause-specific multivariate mortality study. Alzheimers Res Ther  2014; 6(4): 41.
[http://dx.doi.org/10.1186/alzrt271] [PMID: 25435921] 
[18] 
Boström F, Hansson O, Blennow K, et al. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement Geriatr Cogn Disord  2009; 28(4): 314-9.
[http://dx.doi.org/10.1159/000249145] [PMID: 19844105] 
[19] 
Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer’s disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis  2010; 21(4): 1119-28.
[http://dx.doi.org/10.3233/JAD-2010-100207] [PMID: 21504133] 
[20] 
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res  1975; 12(3): 189-98.
[http://dx.doi.org/10.1016/0022-3956(75)90026-6] [PMID: 1202204] 
[21] 
Wattmo C, Blennow K, Hansson O. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease. BMC Neurol  2020; 20(1): 10.
[http://dx.doi.org/10.1186/s12883-019-1591-0] [PMID: 31918679] 
[22] 
Wallin AK, Hansson O, Blennow K, Londos E, Minthon L. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer’s disease? Int J Geriatr Psychiatry  2009; 24(6): 638-47.
[http://dx.doi.org/10.1002/gps.2195] [PMID: 19123199] 
[23] 
Frances A. American Psychiatric Association: Diagnostic and statistical manual of mental disorders: DSM-IV Prepared by the Task Force on DSM-IV.  4th ed. Washington, D.C.: American Psychiatric Association 1994.
[24] 
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology  1984; 34(7): 939-44.
[http://dx.doi.org/10.1212/WNL.34.7.939] [PMID: 6610841] 
[25] 
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist  1969; 9(3): 179-86.
[http://dx.doi.org/10.1093/geront/9.3_Part_1.179] [PMID: 5349366] 
[26] 
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol  2010; 6(3): 131-44.
[http://dx.doi.org/10.1038/nrneurol.2010.4] [PMID: 20157306] 
[27] 
Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem  2005; 51(2): 336-45.
[http://dx.doi.org/10.1373/clinchem.2004.039347] [PMID: 15563479] 
[28] 
Andreasen N, Minthon L, Clarberg A, et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology  1999; 53(7): 1488-94.
[http://dx.doi.org/10.1212/WNL.53.7.1488] [PMID: 10534256] 
[29] 
Bouwman FH, van der Flier WM, Schoonenboom NS, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology  2007; 69(10): 1006-11.
[http://dx.doi.org/10.1212/01.wnl.0000271375.37131.04] [PMID: 17785669] 
[30] 
Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A β1-40, and A β1-42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol  1998; 44(1): 17-26.
[http://dx.doi.org/10.1002/ana.410440108] [PMID: 9667589] 
[31] 
Sutphen CL, McCue L, Herries EM, et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease. Alzheimers Dement  2018; 14(7): 869-79.
[http://dx.doi.org/10.1016/j.jalz.2018.01.012] [PMID: 29580670] 
[32] 
Stern Y, Albert S, Tang MX, Tsai WY. Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology  1999; 53(9): 1942-7.
[http://dx.doi.org/10.1212/WNL.53.9.1942] [PMID: 10599762] 
[33] 
Rhodius-Meester HFM, Liedes H, Koene T, et al. Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease. Alzheimers Res Ther  2018; 10(1): 23.
[http://dx.doi.org/10.1186/s13195-018-0348-0] [PMID: 29458426] 
[34] 
Parsaik AK, Mascarenhas SS, Khosh-Chashm D, et al. Mortality associated with anxiolytic and hypnotic drugs-A systematic review and meta-analysis. Aust N Z J Psychiatry  2016; 50(6): 520-33.
[http://dx.doi.org/10.1177/0004867415616695] [PMID: 26590022] 
[35] 
Zekry D, Herrmann FR, Graf CE, et al. High levels of comorbidity and disability cancel out the dementia effect in predictions of long-term mortality after discharge in the very old. Dement Geriatr Cogn Disord  2011; 32(2): 103-10.
[http://dx.doi.org/10.1159/000326950] [PMID: 21952417] 
[36] 
Holm S, Liss PE, Norheim OF. Access to health care in the Scandinavian countries: ethical aspects. Health Care Anal  1999; 7(4): 321-30.
[http://dx.doi.org/10.1023/A:1009460010196] [PMID: 10787795] 

Rights & Permissions Print Cite

Article Metrics

32

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1567205018666211022164952	Print ISSN 1567-2050
Publisher Name Bentham Science Publisher	Online ISSN 1875-5828

当代阿耳茨海默病研究

脑脊液生物标志物水平作为阿尔茨海默病疗养院安置和存活时间的标志物

摘要

当代阿耳茨海默病研究

脑脊液生物标志物水平作为阿尔茨海默病疗养院安置和存活时间的标志物

摘要 Play Pause

Related Journals

Related Books

摘要